Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …

Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes
mellitus, representing a major cause of visual impairment in developed countries …

Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD)
are common retinal vascular diseases responsible for most blindness in the working-age …

Currently, the treatment for ocular neovascular diseases, including diabetic macular edema
(DME) and age-related macular degeneration (AMD), mainly involves repeated intravitreal …

Engineering approaches using antibody drug conjugates (ADCs) and bispecific antibodies
(bsAbs) are designed to overcome the limitations of conventional chemotherapies and …

It has previously been reported that antioxidant vitamins can help reduce the risk of vision
loss associated with progression to advanced age-related macular degeneration (AMD), a …

Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered
the first-line therapeutic strategy for treating macular exudative diseases; including wet age …

Bispecific antibodies have recently attracted intense interest. CrossMab technology was
described in 2011 as novel approach enabling correct antibody light-chain association with …

Objectives: Describe the risk factors for developing wet age-related macular degeneration.
Outline the typical presentation of a patient with wet age-related macular degeneration …

Introduction Several approaches have been investigated for treating wet age-related
macular degeneration (w-AMD), diabetic macular edema (DME) and retinal vein occlusions …